Evidence map›Paper›PMID 36826709›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2023

Characterization of cuproptosis identified immune microenvironment and prognosis in acute myeloid leukemia.

Dongmei Luo, Songyang Liu, Jie Luo, Hong Chen, Zherou He, Zicheng Gao, Ziyu Wen, Xiaoli Liu, Na Xu

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Dongmei Luo *Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong, China.
Songyang Liu *The First School of Clinical Medicine, Southern Medical University, Guangzhou, 510515, Guangdong, China.
Jie LuoDepartment of Hematology, First Affiliated Hospital of Hainan Medical College, Haikou, 570100, Hainan, China.
Hong ChenDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong, China.
Zherou HeDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong, China.
Zicheng GaoDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong, China.
Ziyu WenDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong, China.
Xiaoli LiuDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong, China.
Na XuDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong, China. sprenaa@163.com.ORCID http://orcid.org/0000-0001-5115-3830
Nanfang Hospital · CNHainan Medical College Hospital · CNSouthern Medical University · CN

Funding

National Natural Science Foundation of China No. 81700104Natural Science Foundation of Guangdong Province No.2019A043135067
6 · The paper itself

Abstract

backgroundRecent studies have reported that cuproptosis, a novel cell death pathway, strongly correlates with mitochondrial metabolism. In addition, the studies reported that cuproptosis plays a role in the development of several cancers and is regulated by protein lipoylation. During cuproptosis, copper binds to the lipoylated proteins and mediates cancer progression. However, the role of cuproptosis in acute myeloid leukemia (AML) patients is yet to be explored.

methodsThis study curated seven cuproptosis-related-genes (CRGs): FDX1, DLAT, PDHB, PDHA1, DLD, LIAS, and LIPT1 to determine cuproptosis modification patterns and the CRGs signature in AML. The CIBERSORT and ssGSEA algorithms were utilized to evaluate the infiltration levels of different immune cell subtypes. A cuproptosis score system based on differentially expressed genes (DEGs) was constructed using the least absolute shrinkage and selection operator (LASSO) regression analysis. The developed cuproptosis score system was validated using two immunotherapy datasets, IMvigor210 and GSE78220.

resultsThree distinct cuproptosis regulation patterns were identified using the Beat AML cohort. The results demonstrated that the three cuproptosis regulation patterns were correlated with various biological pathways and clinical outcomes. Tumor microenvironment (TME) characterization revealed that the identified cuproptosis regulation patterns were consistent with three immune profiles: immune-desert, immune-inflamed, and immune-excluded. The AML patients were grouped into low- and high-score groups based on the cuproptosis score system abstracted from 486 cuproptosis-related DEGs. Patients with lower cuproptosis scores were characterized by longer survival time and attenuated immune infiltration. It was found that lower cuproptosis scores were strongly correlated with lower somatic mutation frequency. Moreover, patients with lower cuproptosis scores presented more favorable immune responses and dual clinical benefits among external validation cohorts.

conclusionsCuproptosis phenotypes are significantly correlated with immune microenvironment complexity and variety. Cuprotopsis regulates the response of cancer cells to the immune system. Quantitatively assessing cuproptosis phenotypes in AML improves the understanding and knowledge regarding immune microenvironment characteristics and promotes the development of therapeutic interventions.

Indexed as

Leukemia, Myeloid, AcuteAlgorithmsApoptosisCell DeathHumansImmunotherapyPrognosisTumor MicroenvironmentAcute myeloid leukemiaChemotherapyCuproptosisImmune microenvironmentImmunotherapyPrognostic signature

Identifiers

PMID36826709
OpenAlexW4321749721

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.